drug · small molecule
regorafenib
Marketedupdated 3mo agoby Bayer AG🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 30 investigational indications.
targets
Discoidin domain-containing receptor 2Ephrin type-A receptor 2Fibroblast growth factor receptor 2Mitogen-activated protein kinase 11Platelet-derived growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying regorafenib
- phase3Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
- phase2Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
- phase3RegoNivo vs Standard of Care Chemotherapy in AGOC
- phase3Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase3A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- phase2A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
- phase2Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 2, 2030
~3.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 9, 2032compositionUS 9957232
- Apr 8, 2031formulationUS 94581074.7y
- Feb 16, 2031compositionUS 86375534.5y
- Jun 2, 2030method-of-use (U-1506)US 86801243.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that